Liver Disease Treatment Market to Reach $36.45 Billion Globally by 2030 at a CAGR of 5.7%: AMR

Rising incidence of liver disease and rise in governmental and non-governmental awareness programs have boosted the growth of the global liver disease treatment market

PORTLAND, Oregon., January 17, 2022 /PRNewswire/ — Allied Market Research recently released a report titled, liver disease treatment market by type of treatment (antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, chemotherapy drugs) and type of disease (hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders and others) : Global Opportunity Industry Analysis and Forecast, 2021-2030″. According to the report, the global liver disease treatment industry generated $20.67 billion in 2020, and is expected to collect $36.45 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030.

Allied_Market_Research_Logo

For a good perspective and competitive insights, get a sample report on: https://www.alliedmarketresearch.com/request-sample/388

Drivers, constraints and opportunities

Rising incidence of liver disease, increase in governmental and non-governmental awareness programs and increasing geriatric population coupled with increased alcohol consumption and unhealthy eating habits have spurred the growth of the global liver disease treatment market. However, stringent regulatory approvals related to drugs and vaccines for the treatment of liver diseases and resistance to antiviral drugs used in the treatment of hepatitis B and C are hampering the market growth. On the contrary, the presence of strong pipelined products is expected to open up new opportunities for market players in the future.

Covid-19 scenario:

  • The Covid-19 epidemic has a moderate impact due to the reduced need for drugs used in the treatment of the liver, the limited availability of medical care and the shortage of health personnel.

  • The increased burden of hospitalizations related to Covid-19 has had a negative impact on the health sector.

  • On the contrary, research studies and activities such as clinical trials on the safety and efficacy of liver disease treatment have boosted the demand for liver disease treatment.

The antiviral segment takes the lion’s share

By type of treatment, the antiviral drugs segment led the market in 2020, accounting for more than two-fifths of the global liver disease treatment market, driven by the rise in the prevalence of virus-infected liver diseases and the availability of branded and generic drugs. However, the immunosuppressants segment is expected to register the highest CAGR of 7.5% during the forecast period, owing to the increase in autoimmune diseases and increase in liver transplants.

Do you have a specific question or requirement? Ask our industry expert: https://www.alliedmarketresearch.com/purchase-enquiry/388

Cancer Segment to Show Highest CAGR through 2030

By end-user, the cancer segment is expected to exhibit the highest CAGR of 7.8% during the forecast period, driven by rising alcohol consumption, obesity and cases of hepatitis. However, the hepatitis segment held the lion’s share in 2020, contributing more than four-fifths of the global liver disease treatment market, owing to the rise in the number of hepatitis cases globally.

North America held the largest share

By region, the market across North America held the largest share in 2020, accounting for more than two-fifths of the market, owing to increasing geriatric population, adoption of advanced technologies, robust R&D infrastructure for life science researchers life and better treatment of liver disease. However, the global liver disease treatment market across Asia Pacific he is expected to manifest Highest CAGR of 7.8% during the forecast period, due to increase in liver disease, increase in public-private investment and government support for pharmaceutical and biotechnology R&D.

Main market players

  • AbbVie Inc.

  • Astellas Pharma Inc.

  • Abbott Laboratories

  • Eli Lilly and company

  • Bristol Myers Squibb

  • Emerging BioSolutions (Cangene bioPharma)

  • F. Hoffman-LA Roche

  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)

  • Gilead Sciences, Inc.

  • Viatris inc.

Avenue Basic Plan | Access to the library | 1 year subscription |

Sign up for the Avenue subscription to access over 12,000 company profiles and over 2,000 niche market research reports on $699 per month, per seat. For one year, the customer must purchase a minimum 2-seat plan.

14-day free trial request: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published some syndicated market studies in the same field that you may be interested in. Below is the title of the report for your reference, considering the impact of Covid-19 on this market which will help you to assess the aftereffects of the pandemic on the short and long term growth trends of this market.”

Reports on trends in the healthcare industry (book now with 10% discount):

Intravenous Immunoglobulin (IVIG) Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

COPD and Asthma Devices Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Nerve Repair and Regeneration Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Epigenetics Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Pulse Oximeter Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

3D Imaging Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Molecular Diagnostics Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Radiotherapy Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

Surgical Robotics Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

PET-CT Scanner Devices Market – Global Opportunity Analysis and Industry Forecast, 2019-2028

About Us

Allied Market Research (AMR) is a full-service market research and business advisory division of Allied Analytics LLP based in Portland, OR. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

Pawan Kumar, CEO of Allied Market Research, directs the organization towards the provision of high quality data and information. We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
United States/Canada (Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
hong kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected]
The Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/

Quote

Quote

Show original content:https://www.prnewswire.com/news-releases/liver-disease-treatment-market-to-reach-36-45-bn-globally-by-2030-at-5-7-cagr-amr-301461905. html

SOURCE Allied Market Research

Comments are closed.